Clinical trials: Assessment Evaluation
Atopic Dermatitis
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
This was a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary…
- Trial name
- NCT04992546
- Testing
- PRN473 (SAR444727)
- Where
- 12 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Diabetic Foot Ulcer
The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
This is an observational, single-arm, on-label study. This clinical study will be conducted at up to 2 sites with a total of 10 subjects per site.
- Trial name
- NCT03640988
- Testing
- dermaPACE
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SANUWAVE, Inc.
Hepatitis A, Hep A
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
The purpose of this study is to evaluate immunogenicity and safety of inactivated hepatitis A vaccine in healthy children aged from 24 months to 15 years when administered an initial dose followed by a booster dose (a total of 2…
- Trial name
- NCT05613127
- Testing
- Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL
- Where
- 2 sites in South Korea, Thailand
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Boryung Biopharma Co., Ltd.
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
- Trial name
- NCT00856661
- Testing
- Desmoteplase
- Where
- 152 sites in United States, Belgium and 12 more
- Volunteers
- 270 people
- Sponsor
- H. Lundbeck A/S
Early Parkinson's Disease
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
This study is to evaluate the safety and efficacy of sustained release (SR)-Exenatide (PT320, Q1W and Q2W) in the treatment of patients with early Parkinson's disease (PD).
- Trial name
- NCT04269642
- Testing
- PT320 2.0 mg, PT320 2.5 mg
- Where
- 5 sites in South Korea
- Volunteers
- 99 people
- Sponsor
- Peptron, Inc.
Atopic Dermatitis, Psoriasis
Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis
Pruritis is a common symptom in patients with atopic dermatitis and psoriasis. Patients with atopic dermatitis and psoriasis often report pruritis-associated sleep impairments and scratching behaviors during nighttime and the…
- Trial name
- DECODE-Scratch (NCT06448689)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- ActiGraph L.L.C
Rabies Post-exposure Prophylaxis
Study to Evaluate GR1801's Efficacy and Safety
The goal of this clinical trial is to compare the efficacy and safety of GR1801 injection with Human Rabies Immunoglobulin(HRIG) in patients with WHO Category 3 rabies exposure. Patients will receive GR1801 injection or HRIG.
- Trial name
- NCT05846568
- Testing
- GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Advanced Solid Tumor
A Study of KL590586 in Patients With Advanced Solid Tumors
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant…
- Trial name
- NCT05265091
- Testing
- KL590586 Capsule
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Cytomegalovirus Infections
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
The purpose of the study is to assess the safety and tolerability of a 3-dose regimen of V160 administered by intramuscular (IM) injection in healthy Japanese male participants by cytomegalovirus (CMV) serostatus.
- Trial name
- NCT03840174
- Testing
- V160
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
This is a single center, Phase 1, randomized, open-label, single-dose, 3 treatment, 3-period, 6-sequence, crossover study designed to compare the PK of SMP-100 dissolved in water for oral administration with SMP-100 tablets under…
- Trial name
- NCT05029518
- Testing
- SMP-100
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Chengdu SciMount Pharmatech Co., Ltd.
Mitochondrial Diseases, Pearson Syndrome
A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome
Mitochondrial diseases are a genetically heterogeneous group of disorders caused by mutations or deletions in mitochondrial DNA (mtDNA) displaying a wide range of severity and phenotypes.
- Trial name
- NCT03384420
- Testing
- CD34+ cells enriched with MNV-BLD
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Minovia Therapeutics Ltd.
Ulcerative Colitis
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis
This is randomized, placebo-controlled, dose-escalation, multicenter, Phase 2 study to evaluate the efficacy and safety of BBT-401-1S in patients with active ulcerative colitis.
- Trial name
- NCT03800420
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- Bridge Biotherapeutics, Inc.
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms
- Trial name
- NCT02834780
- Testing
- H3B-6527
- Where
- 44 sites in United States, Belgium and 9 more
- Volunteers
- 128 people
- Sponsor
- H3 Biomedicine Inc.
Influenza
Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines
The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may occur for up to six months after vaccination.
- Trial name
- NCT00197288
- Testing
- Influenza
- Where
- 15 sites in United States
- Volunteers
- 1,847 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 191 sites in United States, Argentina and 27 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Ascites
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles…
- Trial name
- SIM0388-101 (NCT07007988)
- Testing
- SIM0388
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
DM1, Myotonic Dystrophy
Global Study of Del-desiran for the Treatment of DM1
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy…
- Conditions
- DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia
- Trial name
- HARBOR (NCT06411288)
- Testing
- AOC 1001 (del-desiran)
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 159 people
- Sponsor
- Avidity Biosciences, Inc.
HIV
Condom Performance in a Longitudinal Enhanced Assessment of User Experiences
This study will enroll 252 men who have sex with men (MSM) and 252 men who have sex with women (MSW) in a double-blind, three-way randomized crossover trial with conditions of fitted, thin, and standard condoms.
- Trial name
- C-PLEASURE (NCT02753842)
- Testing
- 5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms
- Volunteers
- 504 people, healthy volunteers welcome
- Sponsor
- Global Protection Corp.
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.